

Supplementary References

1. Wang B, Xiao Z, Ren EC. Redefining the p53 response element. *Proc Natl Acad Sci U S A* 2009; **106**: 14373-14378.
2. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. *Nat Rev Mol Cell Biol* 2008; **9**: 402-412.
3. Horvath MM, Wang X, Resnick MA, Bell DA. Divergent evolution of human p53 binding sites: cell cycle versus apoptosis. *PLoS Genet* 2007; **3**: e127.
4. Schlereth K, Heyl C, Krampitz AM, Mernberger M, Finkernagel F, Scharfe M *et al.* Characterization of the p53 cistrome--DNA binding cooperativity dissects p53's tumor suppressor functions. *PLoS Genet* 2013; **9**: e1003726.
5. Menendez D, Nguyen TA, Freudenberg JM, Mathew VJ, Anderson CW, Jothi R *et al.* Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells. *Nucleic Acids Res* 2013; **41**: 7286-7301.
6. Nikulenkov F, Spinnler C, Li H, Tonelli C, Shi Y, Turunen M *et al.* Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis. *Cell Death Differ* 2012; **19**: 1992-2002.
7. Allen MA, Andrysik Z, Dengler VL, Mellert HS, Guarnieri A, Freeman JA *et al.* Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms. *Elife* 2014; **3**: e02200.
8. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T *et al.* A global map of p53 transcription-factor binding sites in the human genome. *Cell* 2006; **124**: 207-219.
9. Arizti P, Fang L, Park I, Yin Y, Solomon E, Ouchi T *et al.* Tumor suppressor p53 is required to modulate BRCA1 expression. *Mol Cell Biol* 2000; **20**: 7450-7459.
10. Kho PS, Wang Z, Zhuang L, Li Y, Chew JL, Ng HH *et al.* p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. *J Biol Chem* 2004; **279**: 21183-21192.
11. Harris LC, Remack JS, Houghton PJ, Brent TP. Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene. *Cancer Res* 1996; **56**: 2029-2032.
12. Oka S, Leon J, Tsuchimoto D, Sakumi K, Nakabeppu Y. MUTYH, an adenine DNA glycosylase, mediates p53 tumor suppression via PARP-dependent cell death. *Oncogenesis* 2014; **3**: e121.
13. Li B, Lee MY. Transcriptional regulation of the human DNA polymerase delta catalytic subunit gene POLD1 by p53 tumor suppressor and Sp1. *J Biol Chem* 2001; **276**: 29729-29739.
14. Liu G, Chen X. DNA polymerase eta, the product of the xeroderma pigmentosum variant gene and a target of p53, modulates the DNA damage checkpoint and p53 activation. *Mol Cell Biol* 2006; **26**: 1398-1413.
15. Wang B, Xiao Z, Ko HL, Ren EC. The p53 response element and transcriptional repression. *Cell Cycle* 2010; **9**: 870-879.
16. Arias-Lopez C, Lazaro-Trueba I, Kerr P, Lord CJ, Dexter T, Iravani M *et al.* p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene. *EMBO Rep* 2006; **7**: 219-224.
17. da Costa NM, Hautefeuille A, Cros MP, Melendez ME, Waters T, Swann P *et al.* Transcriptional regulation of thymine DNA glycosylase (TDG) by the tumor suppressor protein p53. *Cell Cycle* 2012; **11**: 4570-4578.
18. Fischer M, Quaas M, Steiner L, Engeland K. The p53-p21-DREAM-CDE/CHR pathway regulates G2/M cell cycle genes. *Nucleic Acids Res* 2016; **44**: 164-174.
19. Benson EK, Mungamuri SK, Attie O, Kracikova M, Sachidanandam R, Manfredi JJ *et al.* p53-dependent gene repression through p21 is mediated by recruitment of E2F4 repression complexes. *Oncogene* 2014; **33**: 3959-3969.
20. Jaber S, Toufektchan E, Lejour V, Bardot B, Toledo F. p53 downregulates the Fanconi anaemia DNA repair pathway. *Nat Commun* 2016; **7**: 11091.
21. Navarro F, Lieberman J. miR-34 and p53: New Insights into a Complex Functional Relationship. *PLoS One* 2015; **10**: e0132767.
22. Liang HQ, Wang RJ, Diao CF, Li JW, Su JL, Zhang S. The PTTG1-targeting miRNAs miR-329, miR-300, miR-381, and miR-655 inhibit pituitary tumor cell tumorigenesis and are involved in a p53/PTTG1 regulation feedback loop. *Oncotarget* 2015; **6**: 29413-29427.
23. Poletto M, Legrand AJ, Fletcher SC, Dianov GL. p53 coordinates base excision repair to prevent genomic instability. *Nucleic Acids Res* 2016; **44**: 3165-3175.
24. Zaky A, Busso C, Izumi T, Chattopadhyay R, Bassiouny A, Mitra S *et al.* Regulation of the human AP-endonuclease (APE1/Ref-1) expression by the tumor suppressor p53 in response to DNA damage. *Nucleic Acids Res* 2008; **36**: 1555-1566.
25. Salehi F, Kovacs K, Scheithauer BW, Lloyd RV, Cusimano M. Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update. *Endocr Relat Cancer* 2008; **15**: 721-743.

Supplementary References

26. Chen S, Wang DL, Liu Y, Zhao L, Sun FL. RAD6 regulates the dosage of p53 by a combination of transcriptional and posttranscriptional mechanisms. *Mol Cell Biol* 2012; **32**: 576-587.
27. Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D *et al*. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. *Cell* 2010; **142**: 409-419.
28. Li Y, Liu J, McLaughlin N, Bachvarov D, Saifudeen Z, El-Dahr SS. Genome-wide analysis of the p53 gene regulatory network in the developing mouse kidney. *Physiol Genomics* 2013; **45**:948-964.
29. Simeonova I, Jaber S, Draskovic I, Bardot B, Fang M, Bouarich-Bourimi R *et al*. Mutant mice lacking the p53 C-terminal domain model telomere syndromes. *Cell Rep* 2013; **3**: 2046-2058.
30. Gorjala P, Cairncross JG, Gary RK. p53-dependent up-regulation of CDKN1A and down-regulation of CCNE2 in response to beryllium. *Cell Prolif* 2016; **49**: 698-709.
31. Ferrandiz N, Caraballo JM, Garcia-Gutierrez L, Devgan V, Rodriguez-Paredes M, Lafita MC *et al*. p21 as a transcriptional co-repressor of S-phase and mitotic control genes. *PLoS One* 2012; **7**: e37759.